



## Review Article

# Oxidative stress as a converging mechanism of aging and neurodegeneration: From molecular pathways to therapeutic targets

Meutia A. Faradilla<sup>1</sup>, Karina S. Anastasya<sup>2</sup>, Deasyka Yastani<sup>1</sup>, Yohana Yohana<sup>1</sup>, Endrico X. Tungka<sup>1</sup> and Suweino Suweino<sup>1</sup>

<sup>1</sup>Department of Biochemistry, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia; <sup>2</sup>Department of Nutrition, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia

\*Corresponding author: [meutia.atika@trisakti.ac.id](mailto:meutia.atika@trisakti.ac.id)

## Abstract

Aging is the primary risk factor for major neurodegenerative disorders, yet the precise molecular links between biological aging and progressive neuronal loss remain complex. Oxidative stress, defined as an imbalance between the production of reactive oxygen species (ROS) and antioxidant defenses, has emerged as a central converging mechanism driving both processes. This review aims to synthesize current evidence demonstrating how chronic redox imbalance drives cellular senescence and neuronal vulnerability through mitochondrial dysfunction, lipid peroxidation, and oxidative protein damage. These insights underscore how sustained oxidative insults promote the misfolding and aggregation of disease-defining proteins, including amyloid-beta in Alzheimer's disease and  $\alpha$ -synuclein in Parkinson's disease, thereby amplifying neuroinflammation, synaptic dysfunction, and bioenergetic failure. Furthermore, antioxidant-based therapeutic strategies are critically reassessed, highlighting a paradigm shift from non-specific radical scavenging toward targeted modulation of endogenous defense systems, particularly NRF2 signaling and mitochondria-directed antioxidants. By integrating molecular mechanisms with translational perspectives, this review integrates molecular, cellular, and translational evidence to explain how oxidative stress links biological aging to neurodegenerative disorders such as Alzheimer's and Parkinson's diseases.

**Keywords:** Oxidative stress, aging, neurodegeneration, mitochondria, reactive oxygen species

## Introduction

The unprecedented expansion of the elderly demographic worldwide has been paralleled by a dramatic rise in neurodegenerative disorders, most notably Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) [1]. Although these conditions present with distinct clinical manifestations and hallmark protein signatures, they converge upon a common and arguably central risk factor that is biological aging [2]. Oxidative stress represents a fundamental biological process that becomes progressively dysregulated with aging, driving neuronal vulnerability and neurodegenerative disease progression. This observation suggests that the molecular processes governing senescence do not serve merely as a passive backdrop, but rather act as active drivers of neuronal vulnerability and decline. Within the network of aging-related mechanisms, oxidative stress functions as a central converging mechanism linking normal physiological aging to pathological neurodegeneration [3]. Rather than being a mere byproduct



of metabolic activity, oxidative stress represents a failure of redox homeostasis, a state in which the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) overwhelms the capacity of cellular detoxification and repair systems [4]. Crucially, while basal ROS levels play indispensable roles in signal transduction and cellular adaptation, chronic elevations beyond physiological thresholds instigate cumulative structural damage to DNA, membrane lipids, and functional proteins [5].

Classical theories, such as Harman's Free Radical Theory of Aging [6], have historically attributed aging to the random accumulation of oxidative damage. However, contemporary research has refined this perspective to emphasize that oxidative stress disrupts regulated redox-sensitive signaling pathways, thereby destabilizing fundamental processes essential for neuronal survival [7]. The central nervous system is uniquely susceptible to this form of dysregulation. Although the brain constitutes only about 2% of total body mass, it consumes roughly 20% of basal oxygen, reflecting a metabolic intensity that predisposes it to disproportionate oxidative burden [8]. At the heart of this vulnerability lies the mitochondrion [9]. As the primary source of intracellular ROS generation, mitochondria are paradoxically both the generators and principal victims of oxidative insult. In the aging brain, progressive mitochondrial compromise precipitates a bioenergetic crisis, impairing neuronal capacity to sustain ionic gradients, neurotransmission, and synaptic plasticity. Moreover, damaged electron transport chains become leakier, generating excessive ROS that further tax dwindling antioxidant defenses [10].

This bioenergetic imbalance is intimately linked to the collapse of proteostasis, the constellation of cellular systems that govern protein folding, trafficking, and degradation. Oxidative modifications such as carbonylation and nitration render proteins prone to misfolding while simultaneously inhibiting the ubiquitin proteasome system and autophagy lysosomal pathways responsible for their clearance [11]. The resultant molecular gridlock fosters the accumulation of neurotoxic aggregates, including amyloid-beta in AD and alpha-synuclein in PD. In turn, these aggregates destabilize redox balance, creating a synergistic feedback loop in which protein aggregation exacerbates oxidative stress, and oxidative stress accelerates aggregation [12]. Although oxidative stress is widely recognized as a hallmark of biological aging and neurodegeneration, existing literature frequently addresses mitochondrial dysfunction, proteostatic failure, neuroinflammation, and redox signaling in isolation. This review addresses this gap by integrating molecular, cellular, and translational evidence to clarify how redox imbalance functions as a convergent driver of neuronal dysfunction and loss in Alzheimer's and Parkinson's diseases. The molecular sources of reactive oxygen species, age-related declines in antioxidant capacity, and the convergence of these processes on protein aggregation and neurodegeneration are synthesized. Finally, the limitations of broad-spectrum antioxidant strategies are discussed, and a conceptual shift toward targeted modulation of redox-sensitive pathways, rather than non-specific scavenging, is proposed.

## **Molecular mechanisms of oxidative stress**

Global population aging has been accompanied by a marked increase in neurodegenerative diseases, including AD, PD, and ALS. Although these disorders are clinically distinct, they share biological aging as a common risk factor, indicating that age-related cellular processes actively contribute to neuronal degeneration [13]. Among the molecular pathways involved, oxidative stress has emerged as a central converging mechanism linking physiological aging with neurodegenerative pathology [14]. Oxidative stress arises when the production of reactive oxygen and nitrogen species exceeds the capacity of cellular defense systems, leading to damage to DNA, lipids, and proteins. While low levels of reactive species are essential for normal cellular signaling, sustained elevations disrupt redox homeostasis and impair neuronal function [8]. The central nervous system is particularly susceptible to oxidative injury due to its high metabolic demand and disproportionate oxygen consumption, making oxidative stress a critical driver of age-related neurodegeneration [15].

## **Molecular origins of reactive species**

ROS are primarily generated as metabolic byproducts of aerobic respiration, with the mitochondrial electron transport chain (ETC) serving as the principal intracellular source. During

oxidative phosphorylation, electron leakage occurs most notably at Complex I (nicotinamide adenine dinucleotide reduced (NADH) dehydrogenase) and Complex III (ubiquinone–cytochrome c reductase). This leakage results in the partial reduction of molecular oxygen (O<sub>2</sub>), forming the superoxide anion (O<sub>2</sub><sup>·-</sup>), as described by the reaction  $O_2 + e^- \rightarrow O_2^{\cdot-}$  [16].

Superoxide is rapidly dismutated into the more stable hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), which can diffuse across cellular membranes and function as a signaling molecule. However, the pathogenic potential of oxidative stress markedly increases in the presence of transition metals. Through the Fenton reaction, hydrogen peroxide reacts with ferrous iron (Fe<sup>2+</sup>) or cuprous copper (Cu<sup>+</sup>), generating the highly reactive and destructive hydroxyl radical (·OH):  $Fe^{2+} + H_2O_2 \rightarrow Fe^{3+} + \cdot OH + OH^-$  [17].

The oxidative burden within the brain is not exclusively of mitochondrial origin. Several enzymatic systems contribute significantly to intracellular ROS production, including the NADPH oxidase (NOX) family, peroxisomes, and cytochrome P450 enzymes. In the context of neurodegeneration, the activation of NOX enzymes in microglia is recognized as a major driver of neuroinflammation. This process creates a toxic synergy between oxidative stress and immune activation, amplifying neuronal damage and accelerating neurodegenerative progression [18].

### **Mitochondrial ROS generation**

Mitochondria are central to cellular energy production through oxidative phosphorylation, but they are also the primary source of ROS. During oxidative phosphorylation, electrons are transferred through the mitochondrial electron transport chain, and some electrons leak at Complex I and Complex III. This leakage leads to the partial reduction of molecular oxygen, producing superoxide anions (O<sub>2</sub><sup>·-</sup>). These superoxides are then converted into hydrogen peroxide, which, in turn, can form hydroxyl radicals (·OH) through Fenton reactions, further amplifying oxidative stress [19]. This ROS production becomes self-perpetuating in aging and neurodegenerative diseases, as damaged mitochondria generate more ROS, worsening mitochondrial dysfunction. This creates a vicious cycle where oxidative damage to cellular structures such as lipids, proteins, and DNA intensifies cellular dysfunction, accelerating the progression of diseases like AD and PD. Moreover, mitochondrial damage can reduce ATP production, impeding cellular functions and contributing to neuronal degeneration [5].

### **Lipid peroxidation and membrane vulnerability**

Oxidative stress also leads to lipid peroxidation, a process in which ROS attack the polyunsaturated fatty acids in cellular membranes. Lipid peroxidation generates highly reactive secondary products such as 4-hydroxynonenal and malondialdehyde, which can diffuse across the cells and interact with other cellular components [20]. These lipid peroxidation products disrupt the structural integrity of neuronal membranes, impairing the fluidity and function of the lipid bilayer [21]. This damage compromises membrane-bound proteins, receptors, and ion channels, leading to disturbances in cellular signaling, neurotransmission, and overall neuronal efficiency. In neurodegenerative diseases, this membrane vulnerability accelerates neuronal damage and contributes to synaptic dysfunction. For instance, in AD, lipid peroxidation can facilitate the aggregation of amyloid-beta, further exacerbating the pathological cycle [20]. The lipid-rich membranes of neurons make them particularly susceptible to oxidative damage, reinforcing the progression of diseases like AD and PD [20].

### **Proteostasis collapse**

Proteostasis is essential for maintaining cellular homeostasis by regulating protein synthesis, folding, and degradation. However, oxidative stress disrupts proteostasis, leading to the accumulation of damaged and misfolded proteins. ROS can induce oxidative modifications such as carbonylation and nitration on proteins, altering their structure and function [22]. These misfolded proteins are typically targeted for degradation by the proteasome or autophagy pathways. However, oxidative stress impairs these systems, leading to the accumulation of toxic protein aggregates [23]. In neurodegenerative diseases like AD and PD, this collapse of proteostasis is particularly detrimental. For example, in AD, amyloid-beta accumulates and forms plaques, while in PD, α-synuclein forms Lewy bodies. These protein aggregates not only disrupt cellular function but also impair synaptic plasticity, damage mitochondria, and promote

neuroinflammation [23]. The accumulation of misfolded proteins creates a positive feedback loop that exacerbates oxidative stress, mitochondrial dysfunction, and cellular damage [11].

### **Redox inflammatory crosstalk**

Oxidative stress and neuroinflammation are intimately connected, with ROS playing a crucial role in activating redox-sensitive transcription factors like nuclear factor kappa B (NF- $\kappa$ B). NF- $\kappa$ B, once activated by ROS, translocates to the nucleus and initiates the expression of proinflammatory cytokines such as IL-1 $\beta$ , IL-6, and TNF- $\alpha$  [24]. These cytokines activate microglia, the resident immune cells of the brain, which further increase ROS production and promote inflammation [25]. Chronic neuroinflammation exacerbates neuronal damage by impairing synaptic function, disrupting calcium homeostasis, and sensitizing neurons to excitotoxicity. This inflammatory response becomes self-perpetuating under conditions of sustained oxidative stress, where proinflammatory cytokines further exacerbate ROS production, leading to a cycle of oxidative injury and inflammation [24]. This crosstalk between oxidative stress and inflammation is a critical driver of neurodegenerative diseases like AD and PD, where inflammation amplifies the damage caused by ROS, leading to progressive neuronal death and dysfunction [24].

### **Autophagy and mitophagy failure**

Autophagy and mitophagy are vital cellular processes for maintaining cellular integrity by degrading damaged proteins and organelles. In neurons, where turnover is limited due to the lack of cell division, the efficient functioning of autophagic pathways is critical for long-term survival. However, oxidative stress compromises the integrity of these pathways. ROS can damage the lysosomal system, which is responsible for the final stages of autophagic degradation, impairing its function [26]. As a result, damaged proteins and dysfunctional organelles accumulate within neurons, further exacerbating cellular stress. In particular, mitophagy, the selective removal of damaged mitochondria, is essential to protect cells from oxidative damage. However, oxidative stress impairs mitophagy by disrupting the PINK1/Parkin pathway, which is responsible for marking damaged mitochondria for degradation [27]. The failure to clear dysfunctional mitochondria allows them to persist and continue generating ROS, perpetuating mitochondrial dysfunction and oxidative stress. This accumulation of damaged mitochondria, often referred to as “zombie mitochondria,” further disrupts cellular function, leading to energy depletion and contributing to the neurodegenerative processes observed in diseases like PA [27].

## **Antioxidant defense**

### **Enzymatic vanguard: The first line of redox control**

The first layer of cellular antioxidant defense is formed by a tightly coordinated system of enzymatic antioxidants that operate in a sequential and highly regulated manner. Superoxide dismutases (SODs) act as primary responders by rapidly neutralizing superoxide radicals, which are predominantly produced through electron leakage from the mitochondrial respiratory chain [28]. Because superoxide is highly reactive and short-lived, its rapid conversion into hydrogen peroxide constitutes a crucial protective mechanism rather than a simple chemical reaction. However, hydrogen peroxide occupies a dual role within neuronal physiology [29]. At low concentrations, it functions as a diffusible second messenger involved in synaptic plasticity and signal transduction. Yet, when allowed to accumulate, it becomes a latent threat, particularly in metal-rich neural environments where iron and copper are abundant. To prevent this transition from signaling molecule to cytotoxic precursor, downstream enzymes such as catalase (CAT) and glutathione peroxidase assume decisive roles [30,31]. By decomposing hydrogen peroxide into water and molecular oxygen, these enzymes effectively terminate the oxidative cascade before it can culminate in hydroxyl radical formation, a species widely regarded as the most destructive ROS due to its indiscriminate reactivity [18]. This enzymatic cascade is not simply redundant; instead, it represents an evolutionarily refined system built to maintain redox stability under stress. When any component of this network is compromised, whether due to genetic variation,

post-translational alterations, or age-related functional decline, the balance of redox control can be disrupted. As a result, neurons become particularly vulnerable to oxidative damage [32].

### **Non-enzymatic buffers and thiol-based redox modulation**

Alongside enzymatic antioxidants, cells rely on a broad network of non-enzymatic redox buffers, with glutathione playing a central and indispensable role. As the most abundant intracellular thiol antioxidant, glutathione functions as a dynamic redox reservoir that buffers oxidative fluctuations beyond the capacity of enzymatic systems. By donating electrons, glutathione neutralizes reactive species and is converted into its oxidized form, glutathione disulfide. Consequently, the balance between reduced and oxidized glutathione (the ratio of glutathione to glutathione disulfide) serves as a sensitive marker of cellular redox status. In neurons, which possess limited tolerance to oxidative stress, even subtle changes in this ratio may indicate early metabolic strain [33]. Evidence consistently shows a gradual decline in glutathione levels, suggesting that neurodegeneration is preceded by a slow weakening of intrinsic redox buffering rather than an abrupt oxidative event [34]. Beyond direct antioxidant activity, glutathione supports detoxification processes and modulates redox-sensitive protein thiols, thereby influencing gene regulation, mitochondrial stability, and synaptic function [24]. Loss of glutathione therefore reflects not only diminished antioxidant protection but a broader breakdown in redox regulation [35].

### **Regulatory control and the NRF2 axis**

The effectiveness of antioxidant defenses within the central nervous system is ultimately governed at the transcriptional level. Central to this regulation is the nuclear factor erythroid 2-related factor 2 (NRF2), a master regulator of cellular stress responses. Under basal conditions, NRF2 is sequestered in the cytoplasm; however, in the presence of oxidative stress, it translocates to the nucleus and initiates the expression of a broad repertoire of antioxidant and cytoprotective genes, including those encoding superoxide dismutases, glutathione peroxidase, catalase, and glutathione synthesis enzymes. In youthful and healthy neural tissue, this inducible system provides a remarkable degree of plasticity, enabling neurons to adapt rapidly to fluctuating redox demands [36]. With advancing age, however, the responsiveness of the NRF2 pathway becomes progressively attenuated. This decline does not necessarily reflect a complete loss of function, but rather a diminished sensitivity to oxidative cues. As a result, the antioxidant response becomes delayed or insufficient, allowing ROS production to outpace detoxification. This age-associated regulatory failure creates what can be described as a “redox vulnerability gap”, wherein neurons persist under conditions of chronic, low-grade oxidative stress. Over time, this imbalance promotes cumulative macromolecular damage, mitochondrial dysfunction, and inflammatory signaling hallmarks that converge to drive the initiation and progression of neurodegenerative disorders [37].

## **Oxidative stress in aging: Molecular mechanism of senescence**

### **The modified free radical theory of aging**

Harman's Free Radical Theory of Aging, introduced in 1956, initially proposed that aging results from the gradual accumulation of oxidative damage to essential biomolecules caused by ROS [38]. While this concept laid the foundation for modern aging research, it has since evolved beyond the idea of random and irreversible molecular injury [39]. Current perspectives recognize ROS not only as damaging agents but also as critical regulators of physiological redox signaling. In young and healthy cells, redox balance is tightly controlled [40]. However, this regulatory capacity declines with age, leading to a state of chronic, low-grade oxidative stress. This persistent redox imbalance subtly disrupts cellular signaling pathways and promotes a pro-inflammatory milieu, commonly referred to as inflammaging. In this framework, oxidative stress contributes to aging not merely through direct macromolecular damage, but by driving immune dysregulation and sustained inflammatory signaling. The modified Free Radical Theory therefore reframes

aging as a systemic failure of redox homeostasis, in which oxidative stress and inflammation interact to accelerate functional decline [41].

### **Accumulation of macromolecular damage in the aging brain**

The aging brain is particularly susceptible to oxidative damage due to its high oxygen consumption, lipid-rich composition, and limited regenerative capacity. Over time, an imbalance between ROS production and antioxidant defenses leads to the gradual accumulation of damage to lipids, proteins, and nucleic acids, ultimately compromising neuronal structure and function [42]. Lipid peroxidation represents an early and amplifying form of oxidative injury in neurons. Neuronal membranes are rich in polyunsaturated fatty acids, which are highly vulnerable to oxidative attack. This process generates reactive secondary products such as 4-hydroxynonenal and malondialdehyde, which persist longer than primary radicals and diffuse across cellular compartments. These byproducts disrupt membrane integrity, impair receptor signaling, and interfere with synaptic transmission, thereby reducing neuronal efficiency [43].

Proteins are also major targets of oxidative stress. Oxidative modifications promote protein misfolding and aggregation, a process that is especially harmful in post-mitotic neurons. With aging, the efficiency of proteostatic systems, including the ubiquitin–proteasome pathway and autophagy, progressively declines. As a result, damaged proteins accumulate and form insoluble aggregates that disrupt intracellular transport and synaptic maintenance, further exacerbating cellular stress [22]. Oxidative damage to DNA, particularly mitochondrial DNA, adds another layer of vulnerability. Located near the electron transport chain and lacking robust protective and repair mechanisms, mitochondrial DNA is highly prone to oxidative lesions such as 8-hydroxy-2'-deoxyguanosine. These mutations impair mitochondrial gene expression and energy production, increasing electron leakage and ROS generation. This establishes a self-perpetuating cycle in which oxidative damage and mitochondrial dysfunction reinforce one another, accelerating neuronal aging and degeneration [44].

## **Oxidative stress in neurodegenerative diseases**

### **Alzheimer's disease (AD): Oxidative stress as a self-reinforcing pathological loop**

In AD, oxidative stress is no longer viewed as a secondary consequence of neuronal damage but rather as a central driver of disease progression. It operates through interconnected, self-reinforcing loops that involve amyloid-beta accumulation, mitochondrial dysfunction, and Tau pathology (**Figure 1**). Soluble amyloid-beta oligomers have redox-active properties and readily interact with neuronal membranes and redox-active metals such as iron and copper, triggering localized production of ROS [13]. This pro-oxidative microenvironment damages surrounding cellular components while simultaneously promoting further amyloid-beta aggregation, creating a bidirectional interaction between amyloid pathology and oxidative stress that contributes to early synaptic impairment [45]. As shown in **Figure 1**, the pathological process begins with the accumulation of amyloid-beta within neuronal mitochondria, which further intensifies oxidative injury by disrupting the electron transport chain, particularly cytochrome c oxidase, resulting in reduced ATP synthesis and increased electron leakage. These changes enhance mitochondrial ROS generation, induce mitochondrial DNA damage, and progressively compromise cellular energy balance [10]. In parallel, oxidative stress modulates Tau pathology by activating stress-responsive kinases that promote Tau hyperphosphorylation, leading to microtubule destabilization and impaired axonal transport [1]. Aggregated Tau subsequently worsens mitochondrial dysfunction and oxidative imbalance. Together, these interdependent mechanisms place oxidative stress at the center of a pathological network that links amyloid toxicity, bioenergetic failure, and cytoskeletal disruption in AD [46].

### **Parkinson's disease (PA): Selective vulnerability to oxidative stress**

PA illustrates how intrinsic metabolic characteristics render specific neuronal populations highly vulnerable to oxidative stress. Degeneration of dopaminergic neurons in the substantia nigra pars compacta arises from the convergence of dopamine metabolism, mitochondrial dysfunction, and

impaired antioxidant defenses. Dopamine itself contributes to oxidative burden through enzymatic degradation by monoamine oxidase B, which generates hydrogen peroxide, as well as through spontaneous auto-oxidation that produces reactive quinones capable of damaging proteins and mitochondrial enzymes. This persistent oxidative environment selectively stresses dopaminergic neurons [47].

As shown in **Figure 2**, the pathological process of PA begins with mitochondrial dysfunction, which further amplifies oxidative injury. Genes implicated in familial PD, including PINK1, Parkin, and DJ-1, play critical roles in mitochondrial quality control and redox regulation. Under normal conditions, damaged mitochondria are removed via PINK1–Parkin–mediated mitophagy, limiting excessive reactive oxygen species production. Disruption of this system allows dysfunctional, ROS-generating mitochondria to accumulate, intensifying oxidative stress [48]. Loss of DJ-1–mediated redox sensing further reduces neuronal resilience. Together, these mechanisms establish a self-reinforcing cycle in which oxidative stress and mitochondrial failure drive selective dopaminergic neurodegeneration in PD [36].




Figure 1. Key mechanisms of oxidative stress and neuronal damage in Alzheimer's disease (AD) pathology. Self-reinforcing cycle of oxidative stress and mitochondrial dysfunction, illustrating the roles of amyloid-beta, metals, tau pathology, and mitochondrial dysfunction in AD. The figure is generated using BioRender.

### Self-perpetuating cycle of ROS and inflammation

Once neuroinflammation is established, it further amplifies oxidative stress through the activation of enzymatic sources of reactive oxygen species. Proinflammatory cytokines promote the activation of microglial NADPH oxidase 2 (NOX2), an enzyme complex specifically dedicated to regulated ROS generation. Unlike mitochondrial ROS, which are produced as byproducts of cellular metabolism, NOX2-derived ROS are intentionally generated as part of immune signaling. Under conditions of sustained activation, however, this response becomes maladaptive. Elevated ROS levels inflict additional damage on neuronal membranes, proteins, and mitochondria, leading to the release of danger-associated molecular patterns that further stimulate microglial activation [50]. This feedback loop establishes a self-perpetuating cycle in which oxidative stress and inflammation reinforce one another, progressively spreading neuronal injury and contributing to the chronic and progressive nature of neurodegenerative disorders [50].




Figure 2. Key mechanisms of oxidative stress and mitochondrial impairment in Parkinson's disease (PD) pathology. The self-reinforcing cycle of oxidative stress and mitochondrial dysfunction in PD, illustrating how dopamine metabolism, PINK1/Parkin failure, and DJ-1 loss contribute to dopaminergic neuron degeneration in the substantia nigra. The figure is generated using BioRender.

### Autophagy and mitophagy failure: Breakdown of cellular quality control

While inflammation accelerates extracellular and intercellular damage, oxidative stress simultaneously undermines the intracellular systems responsible for maintaining neuronal integrity. Autophagy, the primary pathway for degrading aggregated proteins and dysfunctional organelles, is particularly vulnerable to redox dysregulation. In post-mitotic cells such as neurons, where damaged components cannot be diluted through cell division, the integrity of autophagic flux is essential for long-term survival [51].

### Lysosomal dysfunction and autophagic arrest

Effective autophagy depends on intact lysosomal function. However, oxidative stress generates lipid peroxidation products such as 4-hydroxynonenal that covalently modify lysosomal membranes and hydrolytic enzymes. These modifications compromise lysosomal acidity and enzymatic efficiency, impairing the final stages of autophagic degradation. As autophagic flux slows, damaged proteins and organelles accumulate within neurons, placing additional stress on already compromised cellular systems. This accumulation not only disrupts intracellular trafficking and synaptic maintenance but also amplifies oxidative stress by allowing ROS-generating structures to persist. Thus, lysosomal dysfunction represents a critical bottleneck where oxidative damage translates into widespread cellular failure [27].

### Mitophagy failure and energetic collapse

Among autophagic processes, the selective removal of damaged mitochondria is known as mitophagy. It is of particular importance in neurodegeneration. Mitochondria are both the primary producers and principal targets of ROS. Under normal conditions, the PINK1/Parkin pathway identifies dysfunctional mitochondria and targets them for autophagic clearance, preventing excessive ROS leakage [3]. Oxidative stress, however, disrupts this quality-control system. Damage to PINK1/Parkin signaling impairs mitochondrial tagging and clearance, allowing dysfunctional mitochondria to accumulate. These organelles, often described as “zombie mitochondria,” remain metabolically active enough to generate ROS but fail to produce adequate ATP. The persistence of such mitochondria exacerbates oxidative stress while simultaneously precipitating cellular energy failure [52]. As ATP levels decline, energy-dependent processes, including ion homeostasis, axonal transport, and synaptic transmission, become unsustainable. Ultimately, this convergence of oxidative damage, autophagy impairment, and bioenergetic

collapse pushes neurons toward apoptotic or necrotic death [53]. The central roles of oxidative stress in neurodegenerative diseases such as AD and PD are illustrated in **Figure 3**. It highlights key mechanisms, including mitochondrial ROS generation, proteostasis collapse, neuroinflammation, and defective autophagy, all contributing to cellular damage. **Figure 3** also shows how oxidative stress promotes synaptic dysfunction and cognitive decline by driving the accumulation of toxic proteins like amyloid-beta and tau in AD and neuronal loss in PD. Additionally, it emphasizes therapeutic targets, such as NRF2 activators (e.g., dimethyl fumarate), mitochondria-targeted antioxidants (e.g., MitoQ), and proteostasis and autophagy enhancers (e.g., rapamycin, SS-31, Urolithin A), which aim to mitigate oxidative damage and restore cellular function.




Figure 3. Schematic overview illustrating the continuum from the molecular origins of reactive oxygen species (ROS) through cellular damage—encompassing mitochondrial dysfunction and neuroinflammation—to clinical manifestations of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. The figure also highlights the emerging shift toward precision medicine and targeted therapeutic strategies. The illustration was created using BioRender.

## Therapeutic targets and clinical implications

The recognition of oxidative stress as a central driver of neurodegeneration has naturally positioned antioxidant-based strategies as attractive therapeutic candidates. However, decades of clinical experience have revealed the limitations of simplistic antioxidant supplementation. The emerging consensus is that effective intervention requires a shift away from indiscriminate radical scavenging toward targeted modulation of endogenous defense pathways, mitochondrial resilience, and adaptive stress responses. In this context, oxidative stress is no longer viewed merely as a pathological burden to be neutralized, but as a dysregulated signaling state that must be recalibrated [31].

### NRF2 pathway activation: Reinforcing endogenous redox resilience

NRF2 serves as a central regulator of cellular antioxidant defense by coordinating a broad transcriptional program that maintains redox homeostasis and cytoprotection. Under physiological conditions, NRF2 is sequestered in the cytoplasm by Kelch-like ECH-associated protein 1 (KEAP1) and targeted for proteasomal degradation [37]. Oxidative or electrophilic stress modifies key cysteine residues on KEAP1, allowing NRF2 to escape degradation and translocate into the nucleus. There, NRF2 binds antioxidant response elements and induces the expression of genes involved in antioxidant defense and detoxification, including heme oxygenase-1, NAD(P)H quinone oxidoreductase 1, and enzymes regulating glutathione metabolism. Rather than simply scavenging reactive oxygen species, NRF2 activation enhances intrinsic redox

resilience by strengthening the cell's capacity to respond to future oxidative challenges [36]. While NRF2 activation is beneficial in protecting against oxidative stress, chronic activation can have limitations. Continuous NRF2 activation may inadvertently promote tumorigenesis by aiding the survival of damaged cells, which may facilitate cancer progression. The activation of the pathway in non-cancerous tissues should, therefore, be carefully regulated. In terms of activating NRF2, activators can be classified into two primary categories, which include electrophilic and non-electrophilic types. Electrophilic activators, such as sulforaphane, directly modify KEAP1, leading to the activation of NRF2 [53]. However, these compounds can cause unintended damage due to their reactivity, potentially affecting cellular structures beyond their target. On the other hand, non-electrophilic activators, such as bardoxolone methyl, activate NRF2 without directly altering KEAP1, which offers a safer profile with fewer side effects but may have lower potency [37].

### Conventional antioxidants have shown limited efficacy in neurodegenerative

Conventional antioxidant therapies have demonstrated limited benefit in neurodegenerative diseases, largely because they fail to adequately target mitochondria, the main intracellular source of neuronal ROS. This shortcoming has driven the development of mitochondria-targeted antioxidants that preferentially accumulate within the mitochondrial matrix by utilizing the mitochondrial membrane potential. MitoQ, for example, couples a ubiquinone moiety to a triphenylphosphonium cation, enabling direct scavenging of mitochondrial ROS and protection of mitochondrial lipids, proteins, and DNA. Similarly, elamipretide (SS-31) exerts its effects by stabilizing cardiolipin in the inner mitochondrial membrane, thereby preserving electron transport efficiency and limiting ROS production at its origin. Collectively, these strategies reflect a paradigm shift from broad-spectrum antioxidant use toward targeted modulation of mitochondrial redox homeostasis [54]. Comparison of mitochondria-targeted antioxidants MitoQ and SS-31 is summarized in Table 1 [25,55–60].

**Table 1. Comparative summary of mitochondria-targeted antioxidants MitoQ and SS-31**

Feature	Mitoquinone mesylate (MitoQ)	Elamipretide (SS-31)
Primary mechanism	Electrophoretic accumulation driven by mitochondrial membrane potential.	Potential-independent uptake; targets and stabilizes cardiolipin in the inner membrane.
Antioxidant action	Redox-active ubiquinone moiety directly scavenges radicals and is regenerated by Complex II.	Structural stabilization of cristae/supercomplexes to prevent electron leakage and ROS formation.
Physical impact	It can cause mitochondrial swelling and depolarization at high concentrations due to its alkyl chain.	Acts as "mitochondrial armor," protecting against membrane fragmentation and structural decay.
Preclinical evidence	Robust protection in Alzheimer's, Parkinson's, and Huntington's disease models.	Consistent success in Alzheimer's, Parkinson's, Huntington's disease, and brain injury models, improving dynamics and synaptic health.
Clinical status	Failed PD trials (no clinical effect on UPDRS). Currently used as a dietary supplement for vascular health.	FDA approved (Sept 2025) for Barth syndrome. Failed trials in heart failure and primary mitochondrial myopathy.

### Lifestyle interventions and hormetic redox adaptation

Lifestyle interventions, such as physical exercise and caloric restriction, activate endogenous antioxidant defenses through a process known as hormesis. Hormesis refers to the phenomenon where low-level, transient oxidative stress triggers adaptive protective responses within cells. When applied in moderation, physical exercise and mild caloric restriction induce controlled oxidative stress that enhances cellular resilience [61]. These interventions improve mitochondrial efficiency by promoting better ATP production and reducing the production of excess ROS, stimulate autophagy for the clearance of damaged proteins and organelles, and upregulate antioxidant signaling pathways such as the Nrf2 pathway, which enhances the cell's ability to combat oxidative damage. Additionally, they boost the secretion of neurotrophic factors like brain-derived neurotrophic factor (BDNF), which support neuronal growth, survival, and synaptic plasticity, playing a crucial role in brain health [62].

However, it is important to note that the beneficial effects of hormesis are dose-dependent. When physical exercise or caloric restriction exceeds a certain threshold, it can shift from an adaptive to a maladaptive stress response. Prolonged or excessive exercise, for example, can lead to chronic oxidative stress, resulting in mitochondrial dysfunction, muscle damage, and an increase in inflammatory markers. Similarly, prolonged caloric restriction may impair cellular homeostasis, weaken the immune system, and exacerbate metabolic dysfunction. These maladaptive responses may overwhelm the body's protective mechanisms, leading to cellular damage rather than the intended health benefits. Therefore, while moderate exercise and caloric restriction can enhance redox balance and improve health outcomes, extreme or prolonged levels of these stressors may cause harm, highlighting the importance of balance in these lifestyle interventions [63].

### Therapeutic potential and clinical translation

Pharmacological activation of NRF2 has therefore emerged as a promising therapeutic strategy in neurodegenerative disorders. Dimethyl fumarate, an approved treatment for multiple sclerosis, represents a clinically validated example of this approach [64]. By inducing mild electrophilic stress, it activates NRF2 signaling and confers neuroprotective and anti-inflammatory effects. Beyond fumarates, synthetic triterpenoids and other NRF2 activators are under investigation for their ability to restore redox homeostasis in aging and neurodegeneration. Nevertheless, clinical translation requires careful calibration. Chronic or excessive NRF2 activation may disrupt physiological redox signaling or promote maladaptive metabolic states. Thus, the therapeutic challenge lies not in maximal activation, but in restoring dynamic responsiveness to oxidative stress [36].

### Challenges and future directions

Despite an increasingly robust molecular framework linking oxidative stress to neurodegenerative disease, clinical translation of antioxidant-based therapies in AD and PD has been largely underwhelming. Numerous trials, particularly those relying on conventional antioxidant supplementation, have failed to demonstrate consistent or meaningful clinical benefit. This disconnect between compelling preclinical data and disappointing clinical outcomes highlights a critical “translational gap” that extends beyond simple issues of drug efficacy. Rather than invalidating the role of oxidative stress in neurodegeneration, these failures underscore the complexity of redox biology in the human brain and reveal fundamental limitations in how antioxidant strategies have been conceptualized and implemented.

**Table 2. Comparative summary between mechanisms of oxidative stress, their roles in Alzheimer's disease (AD) vs. Parkinson's disease (PD) and potential therapeutic interventions**

Mechanisms of oxidative stress	Role in Alzheimer's disease (AD)	Role in Parkinson's disease (PD)	Potential therapeutic interventions
Mitochondrial dysfunction	Mitochondrial dysfunction leads to bioenergetic failure, impairing synaptic plasticity and contributing to neuronal damage.	Mitochondrial dysfunction in dopaminergic neurons accelerates ROS production and contributes to neuronal loss.	Mitochondria-targeted antioxidants (e.g., MitoQ, SS31) that help reduce ROS and restore mitochondrial function.
Lipid peroxidation	Oxidative damage to membrane lipids leads to neuronal damage and loss of synaptic function.	Lipid peroxidation exacerbates dopaminergic neuron death and disrupts membrane integrity.	Use of lipid antioxidants like alpha-lipoic acid or other peroxy scavengers to prevent oxidative damage.
Proteostasis collapse	Proteostasis collapse contributes to the accumulation of amyloid-beta and tau, which disrupt neuronal function.	Accumulation of misfolded proteins, such as $\alpha$ -synuclein, leads to dopaminergic dysfunction.	Proteostasis regulators, such as proteasome activators or autophagy enhancers (e.g., rapamycin, spermidine).

Mechanisms of oxidative stress	Role in Alzheimer's disease (AD)	Role in Parkinson's disease (PD)	Potential therapeutic interventions
Neuroinflammation	Chronic neuroinflammation amplifies the amyloid plaque formation and accelerates disease progression.	Neuroinflammation in microglia worsens dopaminergic neuron death and amplifies ROS production.	Anti-inflammatory agents targeting NF- $\kappa$ B or microglial activation (e.g., minocycline, curcumin).
Redox-Imbalance (ROS and RNS)	ROS accumulation damages cellular structures (DNA, lipids, proteins) and triggers apoptosis.	ROS generation through dopamine metabolism leads to neuronal damage and contributes to cell death.	Nrf2 activators (e.g., dimethyl fumarate), which boost cellular antioxidant defences and help restore redox homeostasis.
Autophagy and mitophagy failure	Impaired autophagy leads to the accumulation of damaged proteins, exacerbating neurodegeneration.	Deficient mitophagy results in the accumulation of dysfunctional mitochondria, contributing to neurodegeneration.	Autophagy enhancers (e.g., rapamycin) and mitophagy activators (e.g., Urolithin A, PINK1 activators) to clear damaged organelles.

### Temporal mismatch: Treating too late in the disease course

One of the most significant challenges lies in the timing of therapeutic intervention. Neurodegenerative diseases are characterized by long preclinical phases, during which molecular and cellular damage accumulates silently over years or even decades. By the time clinical symptoms emerge and patients are enrolled in trials, substantial neuronal loss and synaptic disintegration have already occurred [66,67]. At this advanced stage, oxidative stress is no longer a primary driver but rather a downstream consequence of irreversible structural damage. Antioxidant therapy administered under these conditions is therefore unlikely to restore lost neurons or reverse established network failure [68]. This temporal mismatch suggests that antioxidant interventions may be more effective as preventive or early-stage strategies, rather than as treatments for symptomatic disease. Future clinical trials must therefore prioritize early diagnosis and intervention, potentially targeting individuals with prodromal disease or those identified as high-risk based on genetic, metabolic, or biomarker profiles [69].

### Bioavailability and blood-brain barrier limitations

Another major obstacle is the limited bioavailability of many antioxidant compounds within the central nervous system. The blood-brain barrier, while essential for protecting neural tissue, poses a formidable challenge for drug delivery. Many antioxidants exhibit poor lipophilicity, rapid systemic clearance, or extensive peripheral metabolism, resulting in insufficient concentrations reaching neuronal targets [70]. Even when compounds successfully cross the blood-brain barrier, their intracellular distribution is often non-specific, failing to reach subcellular compartments such as mitochondria, where oxidative stress is most pronounced. This pharmacokinetic mismatch further diminishes therapeutic efficacy and helps explain the failure of broad-spectrum antioxidants in clinical trials. Advances in drug delivery, such as nanoparticle-based carriers, mitochondria-targeted molecules, and ligand-mediated transport systems, represent promising avenues for overcoming these limitations. However, their clinical translation will require rigorous evaluation of safety, specificity, and long-term effects [71].

### Paradox of reductive stress

A less intuitive, yet increasingly recognized challenge is the phenomenon of reductive stress. While oxidative stress reflects an excess of reactive species, excessive antioxidant supplementation can shift the redox balance in the opposite direction, suppressing physiological ROS signaling. ROS are not inherently pathological; at controlled levels, they play essential roles in synaptic plasticity, immune defense, and cellular adaptation. Overzealous scavenging of ROS can therefore impair normal signaling pathways, disrupt mitochondrial function, and paradoxically exacerbate cellular dysfunction [23]. This concept challenges the simplistic view that “more antioxidants are better” and highlights the need for precision in redox modulation. Therapeutic strategies must aim to restore redox homeostasis rather than eliminate ROS

indiscriminately. This requires a nuanced understanding of individual redox states and the context-dependent roles of oxidative signaling in health and disease [72].

### **Need for redox biomarkers and patient stratification**

Perhaps the most critical gap in current clinical approaches is the lack of reliable biomarkers to assess oxidative status *in vivo*. Neurodegenerative diseases are heterogeneous, and not all patients exhibit the same degree or pattern of redox dysregulation. Without biomarkers to stratify patients, antioxidant therapies are applied indiscriminately, diluting potential benefits within responsive subgroups. Future research must therefore focus on developing and validating biomarkers that reflect systemic and brain-specific oxidative stress, antioxidant capacity, and mitochondrial function. These may include circulating redox markers, imaging-based indicators of oxidative metabolism, or genetic and epigenetic signatures linked to redox regulation. Such biomarkers would enable precision medicine approaches, identifying individuals most likely to benefit from antioxidant or redox-modulating interventions and allowing therapies to be tailored in terms of timing, dosage, and mechanism [73].

### **Toward a systems-level therapeutic strategy**

Looking forward, the field must move beyond reductionist strategies that target oxidative stress in isolation. Neurodegeneration arises from the convergence of redox imbalance, mitochondrial dysfunction, neuroinflammation, impaired autophagy, and synaptic failure. Effective therapies will likely need to engage multiple nodes within this network, either through combination treatments or through interventions that restore upstream regulatory control, such as Nrf2 signaling or mitochondrial quality control pathways [74]. In this context, antioxidant therapy should be reframed not as a standalone solution, but as one component of an integrated disease-modifying strategy. Bridging the translational gap will require early intervention, targeted delivery, biomarker-guided patient selection, and a deeper appreciation of redox biology as a dynamic and context-dependent system [75].

## **Conclusion**

This review demonstrates that oxidative stress serves as a central, unifying mechanism linking biological aging to neurodegenerative disorders. Through sustained redox imbalance, ROS drive mitochondrial dysfunction, proteostatic failure, neuroinflammation, and impaired autophagy, collectively undermining neuronal integrity. The limited success of conventional antioxidants highlights the need for targeted redox modulation rather than indiscriminate radical scavenging. Strategies that enhance endogenous defenses, restore mitochondrial quality control, and activate adaptive pathways such as Nrf2 offer promising avenues for delaying neurodegenerative progression and extending neural healthspan.

### **Acknowledgments**

The authors gratefully acknowledge the Department of Biochemistry, Faculty of Medicine, Trisakti University, for its continuous academic support and supportive environment during the development of this review. We also sincerely thank the researchers and scholars whose work has contributed to the advancement of knowledge in the field of oxidative stress, aging, and neurodegeneration. Their contributions provided essential scientific insights that informed and strengthened this manuscript.

### **Competing interests**

All authors declare that there are no conflicts of interest related to this work.

### **Funding**

This study received no external funding.

### Underlying data

The data supporting the findings of this study are available from the corresponding author upon reasonable request.

### Declaration of artificial intelligence use

This study employed the artificial intelligence (AI) tools Gemini Pro and ChatGPT to support manuscript writing, including language refinement (improving grammar, sentence structure, and overall readability) and technical writing assistance (providing suggestions for structuring complex technical descriptions more effectively). All AI-assisted processes were critically reviewed by the authors to ensure the integrity and reliability of the results. The final decisions and interpretations presented in this article were made solely by the authors.

### How to cite

Faradilla MA, Anastasya KS, Yastani D, *et al.* Oxidative stress as a converging mechanism of aging and neurodegeneration: From molecular pathways to therapeutic targets. *Narra J* 2026; 6 (1): e3042 - <http://doi.org/10.52225/narra.v6i1.3042>.

## References

1. Rostagno A, Ghiso J. Alzheimer's disease pathogenic mechanisms: Linking redox homeostasis and mitochondria-associated metabolic pathways through nuclear factor erythroid 2-related factor 2 (Nrf2). *Antioxidants* 2025;14(7):812.
2. Tenchov R, Sasso JM, Wang X, *et al.* Aging hallmarks and progression and age-related diseases: A landscape view of research advancement. *ACS Chem Neurosci* 2023;15(1):1-30.
3. Spina E, Ferrari RR, Pellegrini E, *et al.* Mitochondrial alterations, oxidative stress, and therapeutic implications in alzheimer's disease: A narrative review. *Cells* 2025;14(3):229.
4. Jurcau MC, Jurcau A, Diaconu RG. Oxidative stress in the pathogenesis of neurodegenerative diseases. *Stresses* 2024;4(4):827-849.
5. Xu X, Pang Y, Fan X. Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances. *Signal Transduct Target Ther* 2025;10(1):190.
6. Harman D. Free radical theory of aging. *Mutat Res* 1992;275:257-266.
7. Harman D. Free radical theory of aging: An update: Increasing the functional life span. *Ann N Y Acad Sci* 2006;1067(1):10-21.
8. Watts ME, Pocock R, Claudianos C. Brain energy and oxygen metabolism: Emerging role in normal function and disease. *Front Mol Neurosci* 2018;11:216.
9. Tripathi K, Ben-Shachar D. Mitochondria in the central nervous system in health and disease: The puzzle of the therapeutic potential of mitochondrial transplantation. *Cells* 2024;13(5):410.
10. Stefanatos R, Sanz A. The role of mitochondrial ROS in the aging brain. *FEBS Lett* 2018;592(5):743-758.
11. Kuzu OF, Granerud LJT, Saatcioglu F. Navigating the landscape of protein folding and proteostasis: from molecular chaperones to therapeutic innovations. *Signal Transduct Target Ther* 2025;10(1):358.
12. Hu C, Lin M, Wang C, *et al.* Current understanding of protein aggregation in neurodegenerative diseases. *Int J Mol Sci* 2025;26(21):10568.
13. Tchekalarova J, Tzoneva R. Oxidative stress and aging as risk factors for alzheimer's disease and parkinson's disease: The role of the antioxidant melatonin. *Int J Mol Sci* 2023;24(3):3022.
14. Hou Y, Dan X, Babbar M, *et al.* Ageing as a risk factor for neurodegenerative disease. *Nat Rev Neurol* 2019;15(10):565-581.
15. Neyra Chauca JM, Vázquez VanDyck M, Espinoza Santana A, *et al.* Oxidative stress, neuroinflammation, and microvascular damage in neurodegenerative diseases: Mechanistic insights and therapeutic approaches 2025;10(11):1-14.
16. Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. *Nat Rev Mol Cell Biol* 2020;21(7):363-383.
17. Fujii J, Homma T, Osaki T. Superoxide radicals in the execution of cell death. *Antioxidants* 2022;11(3):501.
18. Liu S, Liu J, Wang Y, *et al.* Oxidative stress: Signaling pathways, biological functions, and disease. *MedComm* 2025;6(7):e70268.

19. Mailloux RJ. An update on mitochondrial reactive oxygen species production. *Antioxidants* 2020;9(6):472.
20. Valgimigli L. Lipid peroxidation and antioxidant protection. *Biomolecules* 2023;13(9):1291.
21. Wang B, Wang Y, Zhang J, *et al.* ROS-induced lipid peroxidation modulates cell death outcome: mechanisms behind apoptosis, autophagy, and ferroptosis. *Arch Toxicol* 2023;97(6):1439-1451.
22. Sonninen TM, Goldsteins G, Laham-Karam N, *et al.* Proteostasis disturbances and inflammation in neurodegenerative diseases. *Cells* 2020;9(10):2183.
23. Ulfig A, Jakob U. Cellular oxidants and the proteostasis network: Balance between activation and destruction. *Trends Biochem Sci* 2024;49(9):761-774.
24. Bellanti F, Coda ARD, Trecca MI, *et al.* Redox imbalance in inflammation: The interplay of oxidative and reductive stress. *Antioxidants* 2025;14(6):656.
25. Şerban M, Toader C, Covache-Busuioc RA. The redox revolution in brain medicine: Targeting oxidative stress with ai, multi-omics and mitochondrial therapies for the precision eradication of neurodegeneration. *Int J Mol Sci* 2025;26(15):7498.
26. Doblado L, Lueck C, Rey C, *et al.* Mitophagy in human diseases. *Int J Mol Sci* 2021;22(8):3903.
27. Du M, Yu Y, Wang J, *et al.* Autophagy-lysosome pathway dysfunction in neurodegeneration and cancer: Mechanisms and therapeutic opportunities. *Int J Mol Sci* 2025;27(1):366.
28. Jomova K, Alomar SY, Alwasel SH, *et al.* Several lines of antioxidant defense against oxidative stress: Antioxidant enzymes, nanomaterials with multiple enzyme-mimicking activities, and low-molecular-weight antioxidants. *Arch Toxicol* 2024;98(5):1323-1367.
29. Gulcin İ. Antioxidants: a comprehensive review. *Arch Toxicol* 2025;99(5):1893-1997.
30. Gusti AM, Qusti SY, Alshammari EM, *et al.* Antioxidants-related superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), glutathione-S-transferase (GST), and nitric oxide synthase (NOS) gene variants analysis in an obese population: a preliminary case-control study. *Antioxidants* 2021;10(4):595.
31. Ashok A, Andrabi SS, Mansoor S, *et al.* Antioxidant therapy in oxidative stress-induced neurodegenerative diseases: role of nanoparticle-based drug delivery systems in clinical translation. *Antioxidants* 2022;11(2):408.
32. Alhaj Sulaiman A, Katanaev VL. Beyond antioxidants: How redox pathways shape cellular signaling and disease outcomes. *Antioxidants* 2025;14(9):1142.
33. Chakravorty S, Malvi A, Chaturvedi A, *et al.* Glutathione—the master antioxidant. *Int J Med Res Pharm Sci* 2020;7(2):1-11.
34. Wadhwa R, Gupta R, Maurya PK. Oxidative stress and accelerated aging in neurodegenerative and neuropsychiatric disorder. *Curr Pharm Des* 2018;24(40):4711-4725.
35. Moustapha A. Neurodegenerative diseases: Potential effect of glutathione. in: Dulce bagatini m, editor. *Glutathione Syst Oxid Stress Health Dis* 2020;2(5):92240.
36. Mayer C, Riera-Ponsati L, Kauppinen S, *et al.* Targeting the NRF2 pathway for disease modification in neurodegenerative diseases: Mechanisms and therapeutic implications. *Front Pharmacol* 2024;15:1437939.
37. Bitra VR, Moshapa F, Adiukwu PC, *et al.* Nrf2-mediated signaling as a therapeutic target in alzheimer's disease. *Open Neurol J* 2024;18(1):e1874205X319474.
38. Harman D. Aging: A Theory based on free radical and radiation chemistry. *J Gerontol* 1956;11(3):298-300.
39. Pomatto LCD, Davies KJA. Adaptive homeostasis and the free radical theory of ageing. *Free Radic Biol Med* 2018;124:420-430.
40. Li B, Ming H, Qin S, *et al.* Redox regulation: mechanisms, biology and therapeutic targets in diseases. *Signal Transduct Target Ther* 2025;10(1):72.
41. Płóciniczak A, Bukowska-Olech E, Wysocka E. The complexity of oxidative stress in human age-related diseases—a review. *Metabolites* 2025;15(7):479.
42. Abdelhamid RF, Nagano S. Crosstalk between oxidative stress and aging in neurodegeneration disorders. *Cells* 2023;12(5):753.
43. Chandimali N, Bak SG, Park EH, *et al.* Free radicals and their impact on health and antioxidant defenses: A review. *Cell Death Discov* 2025;11(1):19.
44. Tripathi D, Oldenburg DJ, Bendich AJ. Oxidative and glycation damage to mitochondrial dna and plastid dna during plant development. *Antioxidants* 2023;12(4):891.
45. Boccardi V, Mancinetti F, Mecocci P. Oxidative stress, advanced glycation end products (AGEs), and neurodegeneration in alzheimer's disease: A metabolic perspective. *Antioxid Basel Switz* 2025;14(9):1044.

46. Alkhalifa AE, Alkhalifa O, Durdanovic I, *et al.* Oxidative stress and mitochondrial dysfunction in alzheimer's disease: Insights into pathophysiology and treatment. *J Dement Alzheimer's Dis* 2025;2(2):17.
47. Watanabe H, Dijkstra JM, Nagatsu T. Parkinson's disease: Cells succumbing to lifelong dopamine-related oxidative stress and other bioenergetic challenges. *Int J Mol Sci* 2024;25(4):2009.
48. Henrich MT, Oertel WH, Surmeier DJ, *et al.* Mitochondrial dysfunction in Parkinson's disease – a key disease hallmark with therapeutic potential. *Mol Neurodegener* 2023;18(1):83.
49. Skou LD, Johansen SK, Okarmus J, *et al.* Pathogenesis of DJ-1/PARK7-Mediated parkinson's disease. *Cells* 2024;13(4):296.
50. Shi X. Targeting NOX2 to combat oxidative stress and neuroinflammation and provide neuroprotection in neurodegeneration.2024. Available from: <http://www.uni-heidelberg.de/mydata.html>. Accessed: 25 December 2025.
51. Kulkarni A, Chen J, Maday S. Neuronal autophagy and intercellular regulation of homeostasis in the brain. *Curr Opin Neurobiol* 2018;51:29-36.
52. Ramsey CL. Biologically structured water (BSW)-a review (Part 1): structured water (SW) properties, BSW and redox biology, BSW and bioenergetics. *J Basic Appl Sci* 2023;19:174-201.
53. Champilas N, Fang EF, Palikaras K. Mitophagy and neuroinflammation: A compelling interplay. *Curr Neuropharmacol* 2023;21(7):1477-1481.
54. Apostolova N, Victor VM. Molecular strategies for targeting antioxidants to mitochondria: Therapeutic Implications. *Antioxid Redox Signal* 2015;22(8):686-729.
55. Broome SC, Whitfield J, Janssens K, *et al.* MitoQ supplementation does not impact redox responses to acute exercise in skeletal muscle of older individuals. *Redox Biol* 2025;88:103927.
56. Pin F, Huot JR, Bonetto A. The mitochondria-targeting agent MitoQ improves muscle atrophy, weakness and oxidative metabolism in C26 tumor-bearing mice. *Front Cell Dev Biol* 2022;10:861622.
57. Zhou J, Shen R, Makale EC, *et al.* SS31 confers cerebral protection by reversing mitochondrial dysfunction in early brain injury following subarachnoid hemorrhage, via the Nrf2-and PGC-1 $\alpha$ -dependent pathways. *Neurochem Res* 2023;48(5):1580-1595.
58. Li M, Kong D, Meng L, *et al.* Discovery of novel SS-31 (d-Arg-dimethylTyr-Lys-Phe-NH<sub>2</sub>) derivatives as potent agents to ameliorate inflammation and increase mitochondrial ATP synthesis. *RSC Adv* 2024;14(41):29789-29799.
59. Jiang Q, Yin J, Chen J, *et al.* Mitochondria-targeted antioxidants: A step towards disease treatment. *Oxid Med Cell Longev* 2020;2020(1):8837893.
60. Wadan AHS, Shaaban AH, El-Sadek MZ, *et al.* Mitochondrial-based therapies for neurodegenerative diseases: A review of the current literature. *Naunyn Schmiedebergs Arch Pharmacol* 2025;398(9):11357-11386.
61. Singh AK, Sinha JK, Seetharam RN. The potential of intermittent fasting in age-related diseases and precision anti-aging therapeutics. London: Academic Press; 2025.
62. Bevere M, Di Cola G, Santangelo C, *et al.* Redox-based disruption of cellular hormesis and promotion of degenerative pathways: perspectives on aging processes. *J Gerontol Ser A* 2022;77(11):2195-2206.
63. Mehdi MM, Solanki P, Singh P. Oxidative stress, antioxidants, hormesis and calorie restriction: The current perspective in the biology of aging. *Arch Gerontol Geriatr* 2021;95:104413.
64. Linker RA, Haghikia A. Dimethyl fumarate in multiple sclerosis: Latest developments, evidence and place in therapy. *Ther Adv Chronic Dis* 2016;7(4):198-207.
65. Toader C, Tataru CP, Munteanu O, *et al.* Decoding neurodegeneration: A review of molecular mechanisms and therapeutic advances in alzheimer's, parkinson's, and ALS. *Int J Mol Sci* 2024;25(23):12613.
66. Colom-Cadena M, Spires-Jones T, Zetterberg H, *et al.* The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. *Alzheimers Res Ther* 2020;12(1):21.
67. Dejanovic B, Sheng M, Hanson JE. Targeting synapse function and loss for treatment of neurodegenerative diseases. *Nat Rev Drug Discov* 2024;23(1):23-42.
68. Manful CF, Fordjour E, Subramaniam D, *et al.* Antioxidants and reactive oxygen species: Shaping human health and disease outcomes. *Int J Mol Sci* 2025;26(15):7520.
69. Velikic G, Supic G, Maric DL, *et al.* Neurodegeneration as ecosystem failure: A new paradigm for prevention and treatment. *Int J Mol Sci* 2025;26(22):11207.
70. Niazi SK. Non-invasive drug delivery across the blood-brain barrier: A prospective analysis. *Pharmaceutics* 2023;15(11):2599.
71. Vargas R, Martinez-Martinez N, Lizano-Barrantes C, *et al.* Advancing through the blood-brain barrier: Mechanisms, challenges and drug delivery strategies. *Admet Dmpk* 2025;13(5):2988.

72. Pérez-Torres I, Guarner-Lans V, Rubio-Ruiz ME. Reductive Stress in Inflammation-associated diseases and the pro-oxidant effect of antioxidant agents. *Int J Mol Sci* 2017;18(10):2098.
73. Şerban M, Toader C, Covache-Busuioc RA. The redox revolution in brain medicine: Targeting oxidative stress with ai, multi-omics and mitochondrial therapies for the precision eradication of neurodegeneration. *Int J Mol Sci* 2025;26(15):7498.
74. Zhang W, Xiao D, Mao Q, *et al.* Role of neuroinflammation in neurodegeneration development. *Signal Transduct Target Ther* 2023;8(1):267.
75. Hein ZM, Karikalan B, Gopalakrishna PK, *et al.* Toward a unified framework in molecular neurobiology of alzheimer's disease: Revisiting the pathophysiological hypotheses. *Mol Neurobiol* 2026;63(1):282.